Onesource Specialty Pharma Limited has informed the Exchange about Credit Rating
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
India Ratings & Research has assigned a fresh credit rating of 'IND A-' with a Positive Outlook to Onesource Specialty Pharma's bank facilities. The rating covers a term loan of INR 2,015.09 million, fund-based working capital limits of INR 5,200 million, and non-fund-based working capital limits of INR 200 million, with a short-term rating of IND A1. OSPL is a multi-modality pharmaceutical CDMO with operations in drug-device combinations, biologics, softgel capsules, and sterile injectables. The company reported consolidated revenue of INR 14,449 million in FY25 (up 740% YoY) with EBITDA margin of 32%, and plans USD 100 million in capex through FY28 focused on GLP-1 product capacity expansion. The Positive Outlook reflects expectations of healthy revenue/EBITDA growth and improved visibility on GLP-1 contract commercialization, though contingent liabilities of INR 11,648 million from a Sputnik Light arbitration remain a watch item.
An investment-grade rating with a Positive Outlook is supportive of OSPL's funding profile and signals confidence in its growth trajectory, particularly the GLP-1 opportunity. Shareholders may view this positively, though the pending arbitration and product concentration risk remain key monitorables.